Nektar Therapeutics Files 8-K on Financials

Ticker: NKTR · Form: 8-K · Filed: May 8, 2025 · CIK: 906709

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Nektar Therapeutics dropped an 8-K on May 8th detailing their financial results. Check it out!

AI Summary

Nektar Therapeutics filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the report date and date of change both being May 8, 2025. The company is incorporated in Delaware and headquartered in San Francisco, California.

Why It Matters

This 8-K filing provides an update on Nektar Therapeutics' financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any significant new risks or negative developments.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K filing?

The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

When was this 8-K report filed and what is the earliest event date reported?

The report was filed on May 8, 2025, and the earliest event date reported is also May 8, 2025.

Where is Nektar Therapeutics' principal executive office located?

Nektar Therapeutics' principal executive office is located at 455 Mission Bay Boulevard South, San Francisco, California 94158.

What is Nektar Therapeutics' IRS Employer Identification Number (EIN)?

Nektar Therapeutics' IRS Employer Identification Number is 94-3134940.

What is the Commission File Number for Nektar Therapeutics?

The Commission File Number for Nektar Therapeutics is 0-24006.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding NEKTAR THERAPEUTICS (NKTR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing